AL Amyloidosis
May 13, 2022
Assessing How Emerging Therapies Will Transform the AL Amyloidosis Treatment Dynamics
AL Amyloidosis is a rare disease, with around 8,500 new cases diagnosed each year in the 7MM. This disease mostly affects elderly persons median age of 64, with slight male predominance (54%). As per our estimates, the highest AL Amyloidosis incidence was observed in the US in 2021. Moreover, there are more than 30...
Read More...
May 25, 2021
TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug
TLX66 Meets Study Objectives, Holding Out in AL Amyloidosis Telix Pharmaceuticals reported the results from the TRALA trial (Targeted Radiotherapy for AL Amyloidosis), a Phase I/IIa trial evaluating the safety and toxicity of TLX66 as the sole bone marrow conditioning agent prior to autologous hematopoietic stem...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
